Subcutaneous Secukinumab in Psoriatic Arthritis: FUTURE 5 Study Results

The FUTURE 5 study examined the efficacy of subcutaneous secukinumab in inhibiting radiographic progression and improving clinical outcomes in psoriatic arthritis. Results showed significant improvement in ACR20, inhibition of structural damage progression, and resolution of enthesitis and dactyliti

0 views • 30 slides